XKRX
115450
Market cap208mUSD
Oct 08, Last price
3,175.00KRW
1D
8.36%
1Q
102.88%
Jan 2017
-80.93%
IPO
-20.23%
Name
HLB Therapeutics Co Ltd
Chart & performance
P/E
—
P/S
4.01
EPS
—
Div yield, %
—
Shrs. gr., 5y
9.01%
Rev. gr., 5y
10.18%
Revenues
69.71b
+26.91%
Net income
-9.23b
L-59.52%
CFO
-5.46b
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Key people
Won Seok Yang
Co-Chief Executive Officer, Director · since 2014
Internal Auditor · since 2013
Byeong Gi Kim
Assistant Managing Director
Sang Gi Lee
Assistant Managing Director
Director · since 2011
Yil Park
Co-Chief Executive Officer, Director · since 2014
Gyeong Bong Ri
Director · since 2013
Jong Hyo Yoon
Director · since 2011
Se Hui Park
Non-Executive Independent Director · since 2013
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||